Thursday 16 October, 2025
Objectives: Meropenem is a broad-spectrum carbapenem antibiotic widely used in the ICU to treat severe infections. In critically ill patients, the main…
Read morePoster: Drug/Disease Modelling - Infection
Severe acute malnutrition results in lower exposure in children treated with artemether-lumefantrine for uncomplicated malaria
Thursday 16 October, 2025
Objectives: Young children ( Methods: This clinical trial was an open-labelled comparative intervention study of artemether-lumefantrine in 131 SAM and…
Read morePopulation pharmacokinetic properties of piperaquine in falciparum malaria: An individual participant data meta-analysis
Thursday 16 October, 2025
Objectives: Dihydroartemisinin-piperaquine is one of the five first-line therapies currently recommended by the World Health Organization for malaria. Previous studies…
Read morePharmacokinetic-Pharmacodynamic Analysis of Anidulafungin in Pediatric and Adult Patients with Invasive Fungal Infections
Thursday 16 October, 2025
Objectives: Anidulafungin (ANID) is an intravenous (IV) echinocandin synthesized from a fermentation product of Aspergillus nidulans. ANID is approved for…
Read moreA challenge model of TNFα turnover with LPS provocations and drug intervention
Thursday 16 October, 2025
Objectives: Tumor necrosis factor alpha (TNFα) is a pro-inflammatory cytokine associated with the pathogenesis of several immune-mediated diseases. Free TNFα…
Read moreLopinavir/Ritonavir Super-boosting Overcomes Interactions In Children Treated With Rifampicin: A Model-Based Approach For Non-Inferiority Trials
Thursday 16 October, 2025
Objectives: The 1st-line HIV treatment for infants includes lopinavir/ritonavir 4:1 (LPV/r). In high-burden settings, rifampicin (RIF) co-treatment for tuberculosis (TB) is…
Read moreJoint pharmacogenetic model of tenofovir and emtricitabine and their active intracellular metabolites in HIV Patients
Thursday 16 October, 2025
Context: According to the 2016 NIH guidelines, tenofovir (TFV) and emtricitabine (FTC) are part of the recommended antiretroviral therapy (ART) regimen…
Read morePredicting RSV Efficacy for MK-1654 During Post-COVID-19 Pandemic RSV Seasons with Protracted Transmission Pattern using MBMA and Clinical Trial Simulation Approaches that Account for RSV Force-of-Infection
Thursday 16 October, 2025
Objectives: There is a high unmet medical need for respiratory syncytial virus (RSV) prophylaxis in infants with convenient once-per-season dosing….
Read morePredicting RSV efficacy for moderate and tropical climates considering seasonal differences in RSV force-of-infection – Application of an MBMA and clinical trial simulation framework to support MK-1654 decision making
Thursday 16 October, 2025
Objectives: MK-1654 is a respiratory syncytial virus (RSV) F glycoprotein neutralizing monoclonal antibody under development to prevent RSV infection in…
Read morePopulation Pharmacokinetics analysis of M5717, a novel antimalarial agent
Thursday 16 October, 2025
Objectives: M5717 is a translation elongation factor 2 (eEF2) inhibitor in development as an antimalarial. It has a long half-life…
Read more